• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CytoCore Among Industry Leaders in Cervical Cancer Treatment Featured in Executive Healthcare Management

Posted on: Thursday, 6 September 2007, 15:07 CDT

CytoCore Inc. (OTCBB:CYCR), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced that the quarterly magazine Executive Healthcare Management will profile CytoCore in its upcoming Q4 2007 issue. The publication is the industry's leading source for healthcare professionals and physicians for evaluating and achieving their business goals.

CytoCore will be featured in this issue's focused report on the detection and treatment of cervical cancer. Also profiled are Cytyc, Dako, Genentech and Genzyme, leading companies in the field of cancer detection and treatment. Floyd Taub, M.D., CytoCore's CEO, was chosen to write a thought-leader piece on the topic, which will appear in the issue. Other contributors include Dr. Julie Gerberding, director of the Centers for Disease Control and Prevention (CDC); Dr. Denise Cardo, director of Healthcare and Quality Programs, CDC; Dr. Mark Sobel, former head pathologist of the National Cancer Institute; and Dr. Elias Zerhourni, director of the National Institute of Health.

"CytoCore is proud of its recognition by Executive Healthcare Management as one of the leading companies addressing the prevention, detection and treatment of cervical cancer," said Dr. Floyd Taub, CEO of CytoCore. "Many exciting advances have recently occurred in the field, and I'm pleased for the opportunity to share my thoughts on the subject and shed light on new, innovative diagnostic and therapeutic technologies that are redefining a major area of women's health."

The Q4 2007 issue of Executive Healthcare Management featuring CytoCore will appear in early October. The publication with web site and print distribution reaches approximately 75,000 readers and can be viewed online at http://www.executivehm.com

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Source: Business Wire

More News in this Category